Traitements2programmes
Essais2liés
Publications1liées
SourceDBlocale

Traitements

2
MoléculeIndication / populationPhaseObjectifPaysRésultat
TEMMA Endovascular TreatmentThis single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal arterial contributors to migraine. Adults aged 18-60 with refractory migraine despite prior preventive therapies are eligible. The study assesses migraine outcomes over 12 months using patient-reported headache frequency, pain intensity, acute medication use, migraine-related disability (MIDAS), and quality-of-life measures (MSQ v2.1). Migraine Non applicable Traitement symptomatique United States À vérifier
TEMMA Endovascular TreatmentThis single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal arterial contributors to migraine. Adults aged 18-60 with refractory migraine despite prior preventive therapies are eligible. The study assesses migraine outcomes over 12 months using patient-reported headache frequency, pain intensity, acute medication use, migraine-related disability (MIDAS), and quality-of-life measures (MSQ v2.1). Migraine Non applicable Traitement symptomatique United States À vérifier

Essais cliniques

2
MoléculeIndication / populationPhaseNCTTitreStatut
TEMMA Endovascular Treatment Migraine Non applicable NCT07313800 EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization NOT_YET_RECRUITING
Middle Meningeal Artery embolization Migraine À vérifier NCT07652034 EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine NOT_YET_RECRUITING

Publications

1
MoléculeIndication / populationTitreJournalDate
TEMMA Endovascular Treatment Treatment with a self-expanding endoprosthesis in patients with stenosis or occlusion at the arteriovenous graft: 6-Month outcomes of a post-marketing surveillance study. The journal of vascular access